Aclaris Therapeutics, Inc.
ACRSAclaris Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing immuno-oncology and dermatology therapies. Founded in 2012 and headquartered in Wayne, Pennsylvania, the company is known for its focus on immune-mediated diseases and dermatological conditions, leveraging innovative small molecule and antibody-based approaches.
Company News
Aclaris Therapeutics will participate in the Piper Sandler 37th Annual Healthcare Conference in New York City on December 2, 2025, with CEO Dr. Neal Walker presenting a fireside chat.
Aclaris Therapeutics will present additional results from its Phase 2a trial of ATI-2138, an investigational oral drug targeting ITK and JAK3, at the 2025 European Academy of Dermatology and Venereology Congress in Paris.
Aclaris Therapeutics will participate in two healthcare conferences in September 2025, with CEO Dr. Neal Walker presenting at the Cantor Global Healthcare Conference and H.C. Wainwright Global Investment Conference.
Aclaris Therapeutics, a clinical-stage biopharmaceutical company, announced its Q1 2025 financial results and provided a corporate update. The company's CEO and senior leadership team will participate in a virtual fireside chat.
Aclaris Therapeutics, a clinical-stage biopharmaceutical company, has appointed Jesse Hall, M.D. as its new Chief Medical Officer. Dr. Hall's extensive experience in areas like immunology and antibody development will be crucial in leading Aclaris' clinical strategy for its portfolio of immuno-inflammatory product candidates.
